203 related articles for article (PubMed ID: 21196532)
1. Janus kinase activation by cytokine oncostatin M decreases PCSK9 expression in liver cells.
Cao A; Wu M; Li H; Liu J
J Lipid Res; 2011 Mar; 52(3):518-30. PubMed ID: 21196532
[TBL] [Abstract][Full Text] [Related]
2. MG132, a proteasome inhibitor, enhances LDL uptake in HepG2 cells in vitro by regulating LDLR and PCSK9 expression.
Yan H; Ma YL; Gui YZ; Wang SM; Wang XB; Gao F; Wang YP
Acta Pharmacol Sin; 2014 Aug; 35(8):994-1004. PubMed ID: 25042549
[TBL] [Abstract][Full Text] [Related]
3. Suppressor of Cytokine Signaling-3 (SOCS-3) Induces Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Expression in Hepatic HepG2 Cell Line.
Ruscica M; Ricci C; Macchi C; Magni P; Cristofani R; Liu J; Corsini A; Ferri N
J Biol Chem; 2016 Feb; 291(7):3508-19. PubMed ID: 26668321
[TBL] [Abstract][Full Text] [Related]
4. Curcumin enhances cell-surface LDLR level and promotes LDL uptake through downregulation of PCSK9 gene expression in HepG2 cells.
Tai MH; Chen PK; Chen PY; Wu MJ; Ho CT; Yen JH
Mol Nutr Food Res; 2014 Nov; 58(11):2133-45. PubMed ID: 25164566
[TBL] [Abstract][Full Text] [Related]
5. Delineation of molecular pathways that regulate hepatic PCSK9 and LDL receptor expression during fasting in normolipidemic hamsters.
Wu M; Dong B; Cao A; Li H; Liu J
Atherosclerosis; 2012 Oct; 224(2):401-10. PubMed ID: 22954675
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of PCSK9 transcription by berberine involves down-regulation of hepatic HNF1α protein expression through the ubiquitin-proteasome degradation pathway.
Dong B; Li H; Singh AB; Cao A; Liu J
J Biol Chem; 2015 Feb; 290(7):4047-58. PubMed ID: 25540198
[TBL] [Abstract][Full Text] [Related]
7. Suppression of Idol expression is an additional mechanism underlying statin-induced up-regulation of hepatic LDL receptor expression.
Dong B; Wu M; Cao A; Li H; Liu J
Int J Mol Med; 2011 Jan; 27(1):103-10. PubMed ID: 21069265
[TBL] [Abstract][Full Text] [Related]
8. Hepatic overexpression of idol increases circulating protein convertase subtilisin/kexin type 9 in mice and hamsters via dual mechanisms: sterol regulatory element-binding protein 2 and low-density lipoprotein receptor-dependent pathways.
Sasaki M; Terao Y; Ayaori M; Uto-Kondo H; Iizuka M; Yogo M; Hagisawa K; Takiguchi S; Yakushiji E; Nakaya K; Ogura M; Komatsu T; Ikewaki K
Arterioscler Thromb Vasc Biol; 2014 Jun; 34(6):1171-8. PubMed ID: 24675665
[TBL] [Abstract][Full Text] [Related]
9. Transcriptional activation of hepatic ACSL3 and ACSL5 by oncostatin m reduces hypertriglyceridemia through enhanced beta-oxidation.
Zhou Y; Abidi P; Kim A; Chen W; Huang TT; Kraemer FB; Liu J
Arterioscler Thromb Vasc Biol; 2007 Oct; 27(10):2198-205. PubMed ID: 17761945
[TBL] [Abstract][Full Text] [Related]
10. Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters.
Dong B; Wu M; Li H; Kraemer FB; Adeli K; Seidah NG; Park SW; Liu J
J Lipid Res; 2010 Jun; 51(6):1486-95. PubMed ID: 20048381
[TBL] [Abstract][Full Text] [Related]
11. A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo.
Gupta N; Fisker N; Asselin MC; Lindholm M; Rosenbohm C; Ørum H; Elmén J; Seidah NG; Straarup EM
PLoS One; 2010 May; 5(5):e10682. PubMed ID: 20498851
[TBL] [Abstract][Full Text] [Related]
12. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2.
Poirier S; Mayer G; Benjannet S; Bergeron E; Marcinkiewicz J; Nassoury N; Mayer H; Nimpf J; Prat A; Seidah NG
J Biol Chem; 2008 Jan; 283(4):2363-72. PubMed ID: 18039658
[TBL] [Abstract][Full Text] [Related]
13. Reduction of circulating PCSK9 and LDL-C levels by liver-specific knockdown of HNF1α in normolipidemic mice.
Shende VR; Wu M; Singh AB; Dong B; Kan CF; Liu J
J Lipid Res; 2015 Apr; 56(4):801-9. PubMed ID: 25652089
[TBL] [Abstract][Full Text] [Related]
14. High-fructose feeding promotes accelerated degradation of hepatic LDL receptor and hypercholesterolemia in hamsters via elevated circulating PCSK9 levels.
Dong B; Singh AB; Azhar S; Seidah NG; Liu J
Atherosclerosis; 2015 Apr; 239(2):364-74. PubMed ID: 25682035
[TBL] [Abstract][Full Text] [Related]
15. A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake.
Ni YG; Condra JH; Orsatti L; Shen X; Di Marco S; Pandit S; Bottomley MJ; Ruggeri L; Cummings RT; Cubbon RM; Santoro JC; Ehrhardt A; Lewis D; Fisher TS; Ha S; Njimoluh L; Wood DD; Hammond HA; Wisniewski D; Volpari C; Noto A; Lo Surdo P; Hubbard B; Carfí A; Sitlani A
J Biol Chem; 2010 Apr; 285(17):12882-91. PubMed ID: 20172854
[TBL] [Abstract][Full Text] [Related]
16. Signaling pathways implicated in oncostatin M-induced aggrecanase-1 and matrix metalloproteinase-13 expression in human articular chondrocytes.
El Mabrouk M; Sylvester J; Zafarullah M
Biochim Biophys Acta; 2007 Mar; 1773(3):309-20. PubMed ID: 17208315
[TBL] [Abstract][Full Text] [Related]
17. Regulation of hepatic LDL receptors by mTORC1 and PCSK9 in mice.
Ai D; Chen C; Han S; Ganda A; Murphy AJ; Haeusler R; Thorp E; Accili D; Horton JD; Tall AR
J Clin Invest; 2012 Apr; 122(4):1262-70. PubMed ID: 22426206
[TBL] [Abstract][Full Text] [Related]
18. Induction of low density lipoprotein receptor (LDLR) transcription by oncostatin M is mediated by the extracellular signal-regulated kinase signaling pathway and the repeat 3 element of the LDLR promoter.
Li C; Kraemer FB; Ahlborn TE; Liu J
J Biol Chem; 1999 Mar; 274(10):6747-53. PubMed ID: 10037774
[TBL] [Abstract][Full Text] [Related]
19. Phaleria macrocarpa (Scheff.) Boerl fruit aqueous extract enhances LDL receptor and PCSK9 expression in vivo and in vitro.
Chong SC; Dollah MA; Chong PP; Maha A
J Ethnopharmacol; 2011 Sep; 137(1):817-27. PubMed ID: 21763412
[TBL] [Abstract][Full Text] [Related]
20. New CETP inhibitor K-312 reduces PCSK9 expression: a potential effect on LDL cholesterol metabolism.
Miyosawa K; Watanabe Y; Murakami K; Murakami T; Shibata H; Iwashita M; Yamazaki H; Yamazaki K; Ohgiya T; Shibuya K; Mizuno K; Tanabe S; Singh SA; Aikawa M
Am J Physiol Endocrinol Metab; 2015 Jul; 309(2):E177-90. PubMed ID: 26015437
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
